RESUMO

With the objective of stimulating the production and licensing of new technologies, the National Institute of Industrial Property (INPI), the agency responsible for granting patents in Brazil, created a priority or fast track procedure for patent processes related to innovations that can be used against COVID-19. The first effects of this institutional measure are assessed in the present work, based on the identification and analysis of the time elapsed between fast track requests by the Ministry of Health or through petition by the depositors themselves. The results demonstrate that the INPI was able to successfully respond to the public health emergency by granting patents on average 5.3 months after the fast track request, a time considerably shorter than the average required in usual processes.

Con objeto de estimular la producción y el otorgamiento de licencias de nuevas tecnologías, el Instituto Nacional de la Propiedad Industrial (INPI), entidad autónoma responsable de la concesión de patentes en Brasil, creó una modalidad de trámite prioritario para los procesos de concesión de patentes relativas a innovaciones que puedan emplearse en la lucha contra la COVID-19. En este trabajo se evaluaron los primeros efectos de esa medida institucional, al determinar y analizar la duración de los procesos prioritarios de concesión de patentes solicitados por medio de comunicación oficial del Ministerio de Salud o de una petición presentada por los propios solicitantes. Los resultados demuestran que el INPI pudo atender con éxito la emergencia de salud pública, al conceder patentes en un período promedio de 5,3 meses contados a partir de la fecha de presentación de la solicitud de priorización, un tiempo considerablemente inferior al promedio exigido en los procesos habituales.

RESUMO

[RESUMO]. Com o objetivo de estimular a produção e o licenciamento de novas tecnologias, o Instituto Nacional da Propriedade Industrial (INPI), autarquia responsável pela concessão de patentes no Brasil, criou uma moda- lidade de trâmite prioritário para processos de patentes relativos a inovações que possam ser usadas no combate à COVID-19. Os primeiros efeitos dessa medida institucional foram avaliados no presente trabalho, a partir da identificação e análise do tempo dos processos prioritários de patente solicitados por ofício pelo Ministério da Saúde ou por meio de petição pelos próprios depositantes. Os resultados demonstram que o INPI foi capaz de atender de forma exitosa à emergência de saúde pública, concedendo patentes em um período médio de 5,3 meses a contar do pedido de priorização, um tempo consideravelmente inferior à média exigida nos processos usuais.

[ABSTRACT]. With the objective of stimulating the production and licensing of new technologies, the National Institute of Industrial Property (INPI), the agency responsible for granting patents in Brazil, created a priority or fast track procedure for patent processes related to innovations that can be used against COVID-19. The first effects of this institutional measure are assessed in the present work, based on the identification and analysis of the time elapsed between fast track requests by the Ministry of Health or through petition by the depositors themsel- ves. The results demonstrate that the INPI was able to successfully respond to the public health emergency by granting patents on average 5.3 months after the fast track request, a time considerably shorter than the average required in usual processes.

[RESUMEN]. Con objeto de estimular la producción y el otorgamiento de licencias de nuevas tecnologías, el Instituto Nacio- nal de la Propiedad Industrial (INPI), entidad autónoma responsable de la concesión de patentes en Brasil, creó una modalidad de trámite prioritario para los procesos de concesión de patentes relativas a innovaciones que puedan emplearse en la lucha contra la COVID-19. En este trabajo se evaluaron los primeros efectos de esa medida institucional, al determinar y analizar la duración de los procesos prioritarios de concesión de patentes solicitados por medio de comunicación oficial del Ministerio de Salud o de una petición presentada por los propios solicitantes. Los resultados demuestran que el INPI pudo atender con éxito la emergencia de salud pública, al conceder patentes en un período promedio de 5,3 meses contados a partir de la fecha de presen- tación de la solicitud de priorización, un tiempo considerablemente inferior al promedio exigido en los procesos habituales.

Assuntos

RESUMO

RESUMO Com o objetivo de estimular a produção e o licenciamento de novas tecnologias, o Instituto Nacional da Propriedade Industrial (INPI), autarquia responsável pela concessão de patentes no Brasil, criou uma modalidade de trâmite prioritário para processos de patentes relativos a inovações que possam ser usadas no combate à COVID-19. Os primeiros efeitos dessa medida institucional foram avaliados no presente trabalho, a partir da identificação e análise do tempo dos processos prioritários de patente solicitados por ofício pelo Ministério da Saúde ou por meio de petição pelos próprios depositantes. Os resultados demonstram que o INPI foi capaz de atender de forma exitosa à emergência de saúde pública, concedendo patentes em um período médio de 5,3 meses a contar do pedido de priorização, um tempo consideravelmente inferior à média exigida nos processos usuais.

ABSTRACT With the objective of stimulating the production and licensing of new technologies, the National Institute of Industrial Property (INPI), the agency responsible for granting patents in Brazil, created a priority or fast track procedure for patent processes related to innovations that can be used against COVID-19. The first effects of this institutional measure are assessed in the present work, based on the identification and analysis of the time elapsed between fast track requests by the Ministry of Health or through petition by the depositors themselves. The results demonstrate that the INPI was able to successfully respond to the public health emergency by granting patents on average 5.3 months after the fast track request, a time considerably shorter than the average required in usual processes.

RESUMEN Con objeto de estimular la producción y el otorgamiento de licencias de nuevas tecnologías, el Instituto Nacional de la Propiedad Industrial (INPI), entidad autónoma responsable de la concesión de patentes en Brasil, creó una modalidad de trámite prioritario para los procesos de concesión de patentes relativas a innovaciones que puedan emplearse en la lucha contra la COVID-19. En este trabajo se evaluaron los primeros efectos de esa medida institucional, al determinar y analizar la duración de los procesos prioritarios de concesión de patentes solicitados por medio de comunicación oficial del Ministerio de Salud o de una petición presentada por los propios solicitantes. Los resultados demuestran que el INPI pudo atender con éxito la emergencia de salud pública, al conceder patentes en un período promedio de 5,3 meses contados a partir de la fecha de presentación de la solicitud de priorización, un tiempo considerablemente inferior al promedio exigido en los procesos habituales.

RESUMO

JUSTIFICATIVA E OBJETIVOS: O delirium é um achado freqüente em pacientes críticos. Apesar de estar associado a um aumento da morbidade e mortalidade, ainda é pouco reconhecido pelos intensivistas. Esta revisão teve como objetivo revisar os principais aspectos relacionados ao delirium no paciente critico. CONTEÚDO: Definição, incidência, mortalidade, fatores de risco, fisiopatologia, diagnóstico e tratamento do delirium no paciente crítico. CONCLUSÕES: O delirium é um distúrbio da consciência, cognição e percepção que pode acometer até 80 por cento dos pacientes em ventilação mecânica. Os fatores de risco incluem doenças sistêmicas agudas, idade avançada, distúrbios cognitivos preexistentes, privação do sono e certas medicações, como os fármacos com atividade anticolinérgica. Embora novas ferramentas estejam disponíveis para o seu rápido diagnóstico em pacientes críticos, os profissionais de saúde ainda não costumam monitorizar esta condição. Nos últimos anos a prevenção e o diagnóstico têm sido priorizados. O haloperidol continua sendo a medicação de escolha embora exista alguma evidência da eficácia da risperidona.

BACKGROUND AND OBJECTIVES: Delirium is a frequent finding in the critically ill patient. Although it is associated with increased morbidity and mortality, it is often not recognized by intensive care doctors. This review will address the main issues regarding delirium in critically ill patients. CONTENTS: Definition, incidence, mortality, risk factors, diagnosis, and treatment of delirium in the critically ill. CONCLUSIONS: Deliriumis defined as a disturbance of consciousness, attention, cognition and perception that occurs frequently in critically ill patients. It occurs in as many as 80 percent of mechanically ventilated ICU patients. Risk factors for delirium include acute systemic illnesses, older age, pre-existing cognitive impairment, sleep deprivation, and medications with anticholinergic activity. Although new assessment tools are available for rapidly and accurately measuring deliriumin critically ill patients, healthcare professionals still do not regularly monitor for this condition. In recent years, the emphasis in the approach to delirium has shifted to systematic screening and prevention. Haloperidol remains the standard treatment for delirium, but there is some evidence for the efficacy of risperidone.

Assuntos

RESUMO

BACKGROUND AND OBJECTIVES: Delirium is a frequent finding in the critically ill patient. Although it is associated with increased morbidity and mortality, it is often not recognized by intensive care doctors. This review will address the main issues regarding delirium in critically ill patients. CONTENTS: Definition, incidence, mortality, risk factors, diagnosis, and treatment of delirium in the critically ill. CONCLUSIONS: Deliriumis defined as a disturbance of consciousness, attention, cognition and perception that occurs frequently in critically ill patients. It occurs in as many as 80% of mechanically ventilated ICU patients. Risk factors for delirium include acute systemic illnesses, older age, pre-existing cognitive impairment, sleep deprivation, and medications with anticholinergic activity. Although new assessment tools are available for rapidly and accurately measuring deliriumin critically ill patients, healthcare professionals still do not regularly monitor for this condition. In recent years, the emphasis in the approach to delirium has shifted to systematic screening and prevention. Haloperidol remains the standard treatment for delirium, but there is some evidence for the efficacy of risperidone.

RESUMO

Several studies have suggested that l-glutamate is a putative neurotransmitter in Schistosoma mansoni. Recently, we detected the presence of low-affinity binding sites for [(3)H]kainic acid in the heterogeneous (P(1)) subcellular fraction of S. mansoni. In an attempt to characterize N-methyl-d-aspartate (NMDA) receptors in this worm, we performed binding assays with [(3)H]MK-801, a NMDA non-competitive antagonist, in the P(1) fraction of adult S. mansoni. In competition experiments, MK-801 (IC(50) approximately 200 microM) and ketamine (IC(50) approximately 500 microM) exhibited a low affinity for the sites labeled with [(3)H]MK-801. Along with the lack of modulation of this binding by glutamatergic agonists and antagonists and the absence of stereoselectivity for MK-801 isomers, these results suggest that [(3)H]MK-801 could label a site different from the classical NMDA receptor in S. mansoni. Based on the evidences that MK-801 interacts with mammalian muscle and central nervous system nicotinic receptors as a low-affinity noncompetitive antagonist, we have investigated the effects of MK-801 on the nicotine-induced flaccid paralysis of the worm, in vivo. The motility of S. mansoni was quantified by image analysis through a measure of displacement of the worm's extremities. In the presence of (-)-nicotine (10-100 microM), we observed an immediate paralysis of the worms, that was inhibited by 1mM MK-801. Besides nicotine, choline (10-50mM) was also able to inhibit the worm's motility. As a conclusion, we suggest that [(3)H]MK-801 binds to nicotinic receptors, and not NMDA receptors, in subcellular fractions of S. mansoni.

Assuntos

RESUMO

Several studies have suggested that L-glutamate is a putative neurotransmitter in helminths. The present study investigated the presence of non-N-methyl-D-aspartate (NMDA) ionotropic receptors for glutamate in four subcellular fractions from adult male Schistosoma mansoni. Low-affinity (K(d)=221+/-80 nM) binding sites for [3H]kainic acid (KA) were detected in the heterogeneous (P(1)) fraction, which contains pieces of unbroken worm tissues, tegument, nuclei, and some vesicles. This binding was inhibited by classical glutamatergic ligands in the following order of potency: KA>L-glutamate>alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)>quisqualate congruent with 6,7-dinitroquinoline-2,3-dione (DNQX). However, neither NMDA, a selective agonist for NMDA receptors, nor DL-threo-beta-hydroxyaspartate (THA) and 1-trans-pyrollidine-2-dicarboxylic acid (PDC), inhibitors of high-affinity glutamate transporters, modified [3H]KA binding to the P(1) fraction. In addition, no specific binding for 10nM [3H]AMPA was detected in any subcellular fraction from S. mansoni. These results suggested the presence of KA receptors in adult male worms. This is supported by the evidence that direct application of 10 microM KA to whole worms produced a corkscrew-like coiling of their bodies, modifying the motility of the worms. The KA-induced response, measured as a decrease of the body area, was time-dependent and reversible. PDC was ineffective at blocking the KA effects, indicating that KA does not depend on high-affinity glutamate transporters to reach its site of action. On the other hand, DNQX, the non-NMDA antagonist, was able to partially inhibit KA-induced responses. As a whole, the present data support the presence of a glutamatergic signaling pathway in this parasite.

Assuntos